GSK heads to Cambridge with long-awaited positive vibes | Nils Pratley

GlaxoSmithKline is investing four hundred million pounds in a new research and development center in Cambridge. The Guardian reports the expansion brings encouraging news for shareholders and is being hailed as a vote of confidence in British business—particularly notable following AstraZeneca's recent cancellation of its own four hundred fifty million pound vaccine plant expansion in Liverpool.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton